Literature DB >> 1965078

Cross-protection against influenza B type virus infection by intranasal inoculation of the HA vaccines combined with cholera toxin B subunit.

K Kikuta1, Y Hirabayashi, T Nagamine, C Aizawa, Y Ueno, A Oya, T Kurata, S Tamura.   

Abstract

The relationship between the antibody responses to various influenza B type virus HA vaccines and protection against live B virus infection was investigated in Balb/c mice which had been inoculated intranasally with a combination of the HA vaccines and B subunit of cholera toxin (CTB) 4 weeks previously. The inoculation of HA vaccine, prepared from B/Ibaraki/2/85 (B/Ibaraki), B/Nagasaki/1/87 (B/Nagasaki) or B/Aichi/5/88 (B/Aichi) viruses, combined with CTB induced high levels of both nasal IgA and serum HI antibodies to any of B/Ibaraki, B/Nagasaki and B/Aichi viral antigens. Simultaneous inoculation of each CTB-combined HA vaccine provided complete protection against B/Ibaraki virus infection which is demonstrated by both rapid clearance of pulmonary virus and complete survival. On the other hand, the inoculation of HA vaccine prepared from B/Yamagata/16/88 (B/Yamagata) virus together with CTB induced only a low level of nasal IgA antibodies, cross-reactive to B/Ibaraki, B/Nagasaki and B/Aichi viral antigens and protected only partially against B/Ibaraki virus challenge. The involvement of the B type virus-specific immunity in this protection was suggested by the absence of protection against B/Ibaraki virus infection in mice previously inoculated with both A/PR/8/34 (H1N1) virus HA vaccine and CTB. These results suggest that antibodies to various influenza B viruses are cross-reactive to each B type virus antigens and that cross-protection against B virus infection could be conferred depending on the degree of B type virus cross-reactive immunity including secretory IgA antibodies.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1965078     DOI: 10.1016/0264-410x(90)90016-f

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  4 in total

1.  Intranasal immunization with a formalin-inactivated human influenza A virus whole-virion vaccine alone and intranasal immunization with a split-virion vaccine with mucosal adjuvants show similar levels of cross-protection.

Authors:  Shigefumi Okamoto; Sumiko Matsuoka; Nobuyuki Takenaka; Ahmad M Haredy; Takeshi Tanimoto; Yasuyuki Gomi; Toyokazu Ishikawa; Takami Akagi; Mitsuru Akashi; Yoshinobu Okuno; Yasuko Mori; Koichi Yamanishi
Journal:  Clin Vaccine Immunol       Date:  2012-05-02

2.  Development of antibody-secreting cells and antigen-specific T cells in cervical lymph nodes after intranasal immunization.

Authors:  H Y Wu; E B Nikolova; K W Beagley; J H Eldridge; M W Russell
Journal:  Infect Immun       Date:  1997-01       Impact factor: 3.441

3.  Cholesteryl Pullulan Encapsulated TNF-α Nanoparticles Are an Effective Mucosal Vaccine Adjuvant against Influenza Virus.

Authors:  Daiki Nagatomo; Madoka Taniai; Harumi Ariyasu; Mutsuko Taniguchi; Miho Aga; Toshio Ariyasu; Tsunetaka Ohta; Shigeharu Fukuda
Journal:  Biomed Res Int       Date:  2015-09-01       Impact factor: 3.411

4.  TMPRSS2 Independency for Haemagglutinin Cleavage In Vivo Differentiates Influenza B Virus from Influenza A Virus.

Authors:  Kouji Sakai; Yasushi Ami; Noriko Nakajima; Katsuhiro Nakajima; Minori Kitazawa; Masaki Anraku; Ikuyo Takayama; Natthanan Sangsriratanakul; Miyuki Komura; Yuko Sato; Hideki Asanuma; Emi Takashita; Katsuhiro Komase; Kazuaki Takehara; Masato Tashiro; Hideki Hasegawa; Takato Odagiri; Makoto Takeda
Journal:  Sci Rep       Date:  2016-07-08       Impact factor: 4.379

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.